 |
||||
| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat
*Mario Negri Institute for Pharmacological Research, Bergamo, Italy; #Unit of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy; and °Genzyme Corporation, Framingham, Massachusetts.
Correspondence to Dr. Carla Zoja, ‘Mario Negri’ Institute for Pharmacological Research, Via Gavazzeni, 11, 24125 Bergamo, Italy. Phone: 39-035-319888; Fax: 39-035-319331;
ABSTRACT. Renin-angiotensin system (RAS) inhibitors are effective in reducing renal disease progression in early diabetic nephropathy, but they provide imperfect protection at a later stage. Due to the pivotal role of transforming growth factor–
(TGF-) in the pathogenesis of diabetic kidney disease, this study tested the effect of simultaneously interrupting TGF- and angiotensin II on disease progression in diabetic rats with overt nephropathy. Diabetes was induced by streptozotocin injection in uninephrectomized rats. Diabetic rats received murine (1D11) or human (CAT-192) anti-TGF- monoclonal antibodies alone or in combination with lisinopril, 13C4 irrelevant murine antibody, saline or lisinopril from month 4 (when animals had proteinuria) to month 8. Normal animals served as controls. Systolic BP increase was controlled by single treatments and even more by the combined therapies. 1D11 and lisinopril kept proteinuria at levels numerically lower than irrelevant antibody and saline, while CAT-192 was ineffective. The addition of either TGF- antibody to lisinopril normalized proteinuria. Consistent results were obtained for glomerulosclerosis and tubular damage, which were abrogated by the combined therapy. Interstitial volume expansion and infiltration of lymphocytes/macrophages were limited by 1D11 and lisinopril and further reduced by their combination. The increase of type III collagen in the renal interstitium was partially attenuated by 1D11 and lisinopril while normalized by their combination. It is concluded that anti–TGF- antibody when added to a background of chronic angiotensin-converting enzyme (ACE) inhibition fully arrests proteinuria and renal injury of overt diabetic nephropathy, providing a novel route to therapy and remission of disease for diabetic patients who do not respond to RAS inhibition. E-mail: zoja@marionegri.it
This article has been cited by other articles:
 |
|
 |
|
  E. Gagliardini, D. Corna, C. Zoja, F. Sangalli, F. Carrara, M. Rossi, S. Conti, D. Rottoli, L. Longaretti, A. Remuzzi, et al. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes Am J Physiol Renal Physiol, November 1, 2009; 297(5): F1448 - F1456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kawajiri, M. Yashiro, O. Shinto, K. Nakamura, M. Tendo, S. Takemura, M. Node, Y. Hamashima, T. Kajimoto, T. Sawada, et al. A Novel Transforming Growth Factor {beta} Receptor Kinase Inhibitor, A-77, Prevents the Peritoneal Dissemination of Scirrhous Gastric Carcinoma Clin. Cancer Res., May 1, 2008; 14(9): 2850 - 2860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Saxena, D. W. Lienesch, M. Zhou, R. Bommireddy, M. Azhar, T. Doetschman, and R. R. Singh Dual Roles of Immunoregulatory Cytokine TGF-{beta} in the Pathogenesis of Autoimmunity-Mediated Organ Damage J. Immunol., February 1, 2008; 180(3): 1903 - 1912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Huang, W. A. Border, L. Yu, J. Zhang, D. A. Lawrence, and N. A. Noble A PAI-1 Mutant, PAI-1R, Slows Progression of Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2008; 19(2): 329 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wang, F. N. Ziyadeh, E. Y. Lee, P. E. Pyagay, S. H. Sung, S. A. Sheardown, N. J. Laping, and S. Chen Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1657 - F1665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, L. Shi, and S. Wang Overexpression of upstream stimulatory factor 2 accelerates diabetic kidney injury Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1727 - F1735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5262 - 5270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nakanishi, T. Sugiura, J. B. Streisand, S. M. Lonning, and J. D. Roberts Jr TGF-beta-neutralizing antibodies improve pulmonary alveologenesis and vasculogenesis in the injured newborn lung Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L151 - L161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mizobuchi, J. Morrissey, J. L. Finch, D. R. Martin, H. Liapis, T. Akizawa, and E. Slatopolsky Combination Therapy with an Angiotensin-Converting Enzyme Inhibitor and a Vitamin D Analog Suppresses the Progression of Renal Insufficiency in Uremic Rats J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1796 - 1806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ninichuk, A. G. Khandoga, S. Segerer, P. Loetscher, A. Schlapbach, L. Revesz, R. Feifel, A. Khandoga, F. Krombach, P. J. Nelson, et al. The Role of Interstitial Macrophages in Nephropathy of Type 2 Diabetic db/db Mice Am. J. Pathol., April 1, 2007; 170(4): 1267 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. El Chaar, J. Chen, S. V. Seshan, S. Jha, I. Richardson, S. R. Ledbetter, E. D. Vaughan Jr, D. P. Poppas, and D. Felsen Effect of combination therapy with enalapril and the TGF-beta antagonist 1D11 in unilateral ureteral obstruction Am J Physiol Renal Physiol, April 1, 2007; 292(4): F1291 - F1301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Cohen, G. T. Lautenslager, E. Hud, E. Shea, A. Wang, S. Chen, and C. W. Shearman Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency Am J Physiol Renal Physiol, February 1, 2007; 292(2): F789 - F795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Biswas, T. L. Criswell, S. E. Wang, and C. L. Arteaga Inhibition of Transforming Growth Factor-{beta} Signaling in Human Cancer: Targeting a Tumor Suppressor Network as a Therapeutic Strategy. Clin. Cancer Res., July 15, 2006; 12(14): 4142 - 4146. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Awad, L. Huang, H. Ye, E. T. A. Duong, W. K. Bolton, J. Linden, and M. D. Okusa Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy Am J Physiol Renal Physiol, April 1, 2006; 290(4): F828 - F837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Saito, N. Ishizaka, M. Hara, G. Matsuzaki, M. Sata, I. Mori, M. Ohno, and R. Nagai Lipid Accumulation and Transforming Growth Factor-{beta} Upregulation in the Kidneys of Rats Administered Angiotensin II Hypertension, November 1, 2005; 46(5): 1180 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Wolf, S. Chen, and F. N. Ziyadeh From the Periphery of the Glomerular Capillary Wall Toward the Center of Disease: Podocyte Injury Comes of Age in Diabetic Nephropathy Diabetes, June 1, 2005; 54(6): 1626 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shibuya, K. Kanasaki, M. Isono, H. Sato, M. Omata, T. Sugimoto, S.-i. Araki, K. Isshiki, A. Kashiwagi, M. Haneda, et al. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Prevents Renal Insufficiency and Mesangial Matrix Expansion in Diabetic db/db Mice Diabetes, March 1, 2005; 54(3): 838 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-C. Hou, W. Wang, X. R. Huang, P. Fu, T.-H. Chen, D. Sheikh-Hamad, and H. Y. Lan Ultrasound-Microbubble-Mediated Gene Transfer of Inducible Smad7 Blocks Transforming Growth Factor-{beta} Signaling and Fibrosis in Rat Remnant Kidney Am. J. Pathol., March 1, 2005; 166(3): 761 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Codreanu, N. Perico, and G. Remuzzi Dual Blockade of the Renin-Angiotensin System: The Ultimate Treatment for Renal Protection? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S34 - S38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Erman, S. Veksler, U. Gafter, G. Boner, C. Wittenberg, and D. J. van Dijk Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor {beta}1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat Journal of Renin-Angiotensin-Aldosterone System, September 1, 2004; 5(3): 146 - 151. [Abstract] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Diabetes Complications Diabetes Care, June 1, 2004; 27(6): 1506 - 1514. [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu Epithelial to Mesenchymal Transition in Renal Fibrogenesis: Pathologic Significance, Molecular Mechanism, and Therapeutic Intervention J. Am. Soc. Nephrol., January 1, 2004; 15(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
